Table 5—

Trials on high dose chemothaerapy plus haematological stem cell support

First author [ref. no.]	Study period	Patients n	Ext. Stage	Induction regime	High-dose regime	Radiotherapy	Survial
First author [ref. no.]	Study period	Patients n	Ext. Stage	Induction regime	High-dose regime	Radiotherapy	Median months	2-yr %	5-yr %
Brugger 42	1992–1994	18	0	IFX 4 g·m⁻²	IFX 4 g·m⁻²	Chest:		78
				P 50 mg·m⁻²	Carbo 250 mg·m⁻²	50 Gy
				E 500 mg·m⁻²	E 500 mg·m⁻²
				EPI 50 mg·m⁻²	EPI 50 mg·m⁻²	PCI:
				(Wk 1 & 3)	days 1–3 wk 7	30 Gy
					+PBSC+G-CSF
Elias 43	1985–1994	36	0	No standard	CTX 1875 mg·m⁻²	Chest:		53	41
				4 series given	P 55 mg·m⁻²	50–56 Gy
				in referring	BCNU 160 mg·m⁻²	PCI:
				dept.	days 1–3	30 Gy
					+marrow/PBSC (+G-CSF)
Van de Velde 44	1993–1996	39	0	IFX 3–4 g·m⁻² days 1–3	E 120–150 mg·m⁻² days 1–3	Chest:	24.6	51	18
				EPI 30–40 days 1–3	Carbo AUC 5 days 1–2	2 Gy×5
				(Wk 3)	Wks 1, 3, 6 & 9
					IFX+EPI, wk 6
					E+Carbo, wk 9
					PBSC day 5 wk 3, 6, 9+G-CSF
Leyvraz 45	1994–1997	69	39	EPI 75 mg·m⁻² days 1–2	IFX 2.5 mg·m⁻²	Chest: 37 pts	13.5
					Carbo 300 mg·m⁻²	No standard	LIM: 18	32	18
					E 300 mg·m⁻²	PCI: 24 pts	EXT: 11	5	0
					Days 1–4 wk 3, 7, 11	No standard
					PBS+G-CSF
Bessho 46	1995–1997	11	5	EXT:	IFX 3 g·m⁻² days 1–4		15, 17, 18 and >35
				P 60 mg·m⁻² days 1+8	Carbo 400 mg·m⁻² days 1, 3, 5
				Irinp 50 mg·m⁻² days 1+8	E 500 mg·m⁻² days 1, 3, 5
				×3–4 q. 3–4 wks
				LIM:		Chest:	>19, >21, >22, >23
				P 50 mg·m⁻² days 1+8		1.5 Gy×30
				E 80 mg·m⁻² days 1, 2, 8, 9		twice daily
				Wk 1–3

IFX: ifosphamide
CTX: cyclophosphamide
EPI: epirubicine
Carbo: carboplatin
P: cisplatin
E: etoposide
PBSC: peripheral blood stem cells
G-CSF: granulocyte colony stimulating factor
LIM: limited disease
PCI: prophylactic cranial irradiation